| Metric | Current Period | Prior-Year Period | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥3644.0B | ¥3615.9B | +0.8% |
| Operating Income / Operating Profit | ¥226.9B | ¥225.8B | +0.5% |
| Profit Before Tax | ¥63.9B | ¥188.2B | -66.1% |
| Net Income | ¥2.2B | ¥103.6B | -97.9% |
| ROE | 0.1% | 7.3% | - |
For the fiscal year ended March 2026, Revenue was ¥3,644.0B (YoY +¥28.1B, +0.8%), Operating Income was ¥226.9B (YoY +¥1.1B, +0.5%), Ordinary Income was not disclosed but Profit Before Tax was ¥63.9B (YoY -¥124.3B, -66.1%), and Net income attributable to owners of parent was ¥4.9B (YoY -¥100.0B, -95.3%). Revenue ticked up slightly and operating-level profit remained flat, but financial expenses surged to ¥166.4B (prior year ¥52.6B), a 3.2x increase, sharply reducing Profit Before Tax. An elevated effective tax rate of 96.6% further compressed final profit. Operating margin remained steady at 6.2% (prior year 6.2%), but this masked a decline in gross margin to 45.4% (prior year 46.0%) that was offset by SG&A cost containment (ratio 39.7%, prior year 39.9%); substantive profitability improvement was not achieved. By segment, Diabetes Management drove profits with Operating Income up +44.6%, while Healthcare Solutions and Diagnostics & Life Sciences posted declines of -32.8% and -46.3%, respectively, highlighting a clear polarization.
[Revenue] Revenue of ¥3,644.0B (YoY +0.8%) was only slightly higher. By segment, Diabetes Management was resilient at ¥1,015.8B (+2.9%) supporting the group. Healthcare Solutions was essentially flat at ¥1,283.9B (+0.1%), while Diagnostics & Life Sciences declined to ¥1,283.2B (-2.0%), accentuating growth disparities across the business portfolio. Foreign exchange contributed positively via foreign operations translation differences of +¥268.9B, and yen depreciation supported overseas revenue. In the TextBlock performance trend, revenue increased from 361,593 million yen to 364,403 million yen year-on-year, indicating growth driven by the core diabetes area.
[Profitability] Operating Income of ¥226.9B (+0.5%) was only marginally higher, with operating margin unchanged at 6.2%. Cost of sales ratio worsened to 54.6% (prior year 54.0%), lowering gross margin to 45.4% (prior year 46.0%), but a 0.2pt improvement in SG&A ratio to 39.7% (prior year 39.9%) maintained margins. By segment, Diabetes Management achieved high profitability with Operating Income of ¥200.9B (+44.6%) and a margin of 19.8%, whereas Healthcare Solutions delivered ¥62.3B (-32.8%) at a 4.9% margin and Diagnostics & Life Sciences ¥38.9B (-46.3%) at a 3.0% margin, both experiencing steep profit declines and low profitability that diluted group-level margins. Financial expenses surged from ¥52.6B to ¥166.4B (3.2x), compressing Profit Before Tax to ¥63.9B (prior year ¥188.2B, -66.1%). Corporate income tax expense of ¥61.7B implies an effective tax rate of 96.6% on Profit Before Tax of ¥63.9B, an exceptionally high rate, which, combined with the heavy tax burden, reduced net income attributable to owners of parent to ¥4.9B (prior year ¥104.9B, -95.3%). Comprehensive income rose to ¥241.4B (prior year ¥62.8B) largely due to non-cash items such as foreign currency translation differences of +¥268.9B, creating divergence from operating results. In summary: modest revenue and flat operating profit, but final profit declined due to higher interest burden and abnormal tax rate.
Diabetes Management: Revenue ¥1,015.8B (+2.9%), Operating Income ¥200.9B (+44.6%), Operating margin 19.8% — high-profit, high-growth segment leading the group. Core products such as blood glucose monitoring systems drove earnings. Healthcare Solutions: Revenue ¥1,283.9B (+0.1%) essentially flat, but Operating Income ¥62.3B (-32.8%) fell sharply to a 4.9% margin. Increased competition in clinical testing and medical IT and rising costs were contributing factors. Diagnostics & Life Sciences: Revenue ¥1,283.2B (-2.0%) and Operating Income ¥38.9B (-46.3%) — margin 3.0%, the lowest among segments — with profitability hurt by price pressure and lower demand for pathology testing equipment and diagnostic reagents. Other & Adjustments: Revenue ¥61.1B, Operating loss -¥75.3B reflecting corporate allocations. The three segments’ combined Operating Income was ¥302.1B, but after corporate adjustments this fell to ¥226.9B, indicating approximately ¥75B of unallocated corporate cost burden.
[Profitability] ROE 0.3% (prior year 7.5%) deteriorated significantly due to the sharp fall in net income margin. Operating margin 6.2% is in line with prior year, but Profit Before Tax margin 1.8% (prior year 5.2%) and Net income margin 0.1% (prior year 2.9%) were sequentially compressed by financial expenses and tax burden. Against an EBIT margin of 6.2%, interest expense materially reduced earnings; interest coverage is EBIT ¥226.9B / interest expense ¥58.8B ≒ 3.9x, a low level (prior year approx. 4.6x), indicating high sensitivity to interest rate changes. [Cash Quality] Operating Cash Flow (OCF) ¥424.6B / Net Income ¥2.2B ≒ 193x — an extreme ratio — and accrual ratio ((Net Income - OCF)/Total Assets) = -7.8% indicates favorable accrual quality. Changes in working capital supported cash: trade receivables collected +¥39.9B, inventories down +¥22.3B, trade payables up +¥29.2B, though inventory and receivables days remain elevated (DIO 97 days, prior year 95; DSO 70 days, prior year 71). [Investment Efficiency] ROA (Net Income/Total Assets) 0.04% (prior year 1.9%), ROA (Ordinary Income basis) 1.2% (prior year 3.4%) — significant deterioration. Total asset turnover 0.67x (prior year 0.68x) modestly down; goodwill ¥2,215B (40.8% of total assets) and intangible assets ¥744B depress asset efficiency. [Financial Soundness] Equity Ratio 29.8% (prior year 26.6%) improved due to FX effects but remains low. Interest-bearing debt (current ¥782.5B + non-current ¥1,563.0B) totals ¥2,345.5B, with D/E ratio 2.37x (prior year 2.87x) indicating sustained high leverage. Current ratio 93% (¥1,761.8B / ¥1,896.3B) below 1.0 suggests short-term liquidity concern. Debt/EBITDA 4.71x (Interest-bearing debt ¥2,345.5B / EBITDA ¥498.1B) is high, leaving the company vulnerable to rising rates and refinancing risk.
Operating Cash Flow was ¥424.6B (prior year ¥419.4B, +1.2%), indicating stable cash generation. Gross operating cash before working capital changes was ¥541.8B (prior year ¥499.7B); after deductions such as corporate tax payments -¥70.2B and interest paid -¥53.3B, cash remained solid. Working capital movements—trade receivables decrease +¥39.9B, inventories decrease +¥22.3B, trade payables increase +¥29.2B—contributed cash; the combination of higher payables and lower inventory suggests working capital compression that may not be sustainable. Investing Cash Flow was -¥84.5B, centered on capital expenditure -¥90.9B; capex to depreciation ratio is 0.34x (depreciation ¥271.2B), indicating restrained investment and potential concerns about underinvestment for future growth and renewal. Free Cash Flow (OCF + Investing CF) was ¥340.0B, ample to cover dividend payments of -¥53.1B. Financing Cash Flow was -¥398.2B: while short-term borrowings increased by +¥501.9B and long-term borrowings by +¥1,858.0B, long-term repayments of -¥2,604.0B indicate large-scale refinancing, shifting net interest-bearing debt into short-term and increasing liquidity risk. Cash and cash equivalents were ¥398.2B (prior year ¥395.9B), a modest increase supported by FX effects of +¥60.4B.
Quality of earnings has weakened due to divergence between operating results and final profit. Operating Income ¥226.9B versus Profit Before Tax ¥63.9B leaves a gap of ¥163.0B, mainly attributable to the sharp increase in financial expenses (YoY +¥113.8B) and a change to share of associates’ results (from prior year -¥3.7B to current +¥0.8B). The increase in financial expenses appears structural, driven by changes in debt composition and interest rate levels, and is expected to persist as recurring expense. Corporate income tax expense ¥61.7B on Profit Before Tax ¥63.9B implies an effective tax rate of 96.6%, an abnormal figure likely influenced by limitations on recognition of deferred tax assets and one-off tax-effect accounting adjustments. Financial income of ¥3.4B is minor (0.09% of sales), indicating no material one-off income expansion. Comprehensive income of ¥241.4B, driven by foreign currency translation differences +¥268.9B (non-cash, market-driven), greatly exceeds net income ¥2.2B but is unrelated to underlying profit sustainability. OCF ¥424.6B / EBITDA ¥498.1B ≒ 0.85x indicates solid cash backing for EBITDA, but reliance on working capital moves (higher payables, lower inventory) suggests potential for reversal next period.
Company plan for FY ending March 2027: Revenue ¥3,597.0B, Operating Income ¥270.0B (YoY +19.0%), Net income attributable to owners of parent ¥154.0B, EPS ¥121.73, Dividend ¥21.00. The guidance implies Operating Income improvement of +¥43.1B over current period ¥226.9B, assuming normalization of financial expenses and tax rate and profitability improvements in low-margin segments. Progress at interim was not disclosed, but full-year Operating Income guidance at +19.0% is ambitious and depends on continued high growth in Diabetes business and price increases / cost reductions in the other two segments. Projected net income ¥154.0B assumes a substantial recovery from current ¥4.9B, reflecting normalization of effective tax rate (current 96.6% → standard in the 30% range) and suppression of financial expenses. However, if interest-bearing debt remains at ¥2,345B and Debt/EBITDA 4.71x does not improve, interest burden will persist and the guidance carries significant execution risk.
Annual dividend is ¥42.00 (interim ¥21.00, year-end ¥21.00), total approx. ¥5.3B. Dividend payout ratio relative to Net income attributable to owners of parent ¥4.9B is 1,082%, an extremely high level, clearly not sustainable from current profits and funded by drawing down reserves. Conversely, coverage of dividends by Free Cash Flow ¥340.0B is approximately 6.4x, indicating dividend payments were sufficiently covered on a cash basis this period. Next fiscal year guidance EPS ¥121.73 and Dividend ¥21.00 imply a payout ratio of about 17.2%, returning to normal levels, but this assumes normalization of interest burden and tax rate and therefore contains uncertainty. No share buybacks were executed this period (none disclosed in Financing CF), so returns were dividend-only. Given high leverage and high interest burden, priority should be given to debt reduction and growth investments, and a flexible approach to total shareholder return is recommended.
High leverage and liquidity mismatch: Interest-bearing debt ¥2,345.5B with D/E 2.37x and Debt/EBITDA 4.71x is high. Short-term borrowings ¥782.5B far exceed cash balance ¥398.2B and current ratio 93% reveals a maturity mismatch. Rising rates or refinancing failure could severely weaken liquidity and trigger covenant breaches.
Sharp increase in interest burden and profit pressure: Financial expenses expanded from ¥52.6B to ¥166.4B (3.2x), with interest coverage at 3.9x. Continued rate increases or higher refinancing costs would continue to compress Profit Before Tax and offset operating-level improvements.
Capital dependence on goodwill and intangibles: Goodwill ¥2,215B equals 138% of equity (Net Assets), indicating reliance on intangible asset values. In deteriorating conditions, impairment risk is high and would materially erode equity and further weaken financial health.
Profitability & Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Return on Equity | 0.3% | 6.3% (3.2%–9.9%) | -6.0pt |
| Operating Margin | 6.2% | 7.8% (4.6%–12.3%) | -1.5pt |
| Net Profit Margin | 0.1% | 5.2% (2.3%–8.2%) | -5.1pt |
Profitability lags the industry median across all measures, especially ROE and net profit margin, which are depressed by interest burden and abnormal tax rate.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 0.8% | 3.7% (-0.4%–9.3%) | -2.9pt |
Revenue growth trails the industry median, with underperformance outside the core segment suppressing group growth.
※Source: Company compilation
Final profit declined sharply due to a surge in financial expenses and an abnormal tax rate, but OCF ¥424.6B and FCF ¥340.0B remain solid, indicating maintained cash generation capacity. Full-year guidance assumes Operating Income +19.0% and normalization of interest burden and tax rate, but improvement in high leverage (Debt/EBITDA 4.71x, D/E 2.37x) and resolution of liquidity mismatch (current ratio 93%) are preconditions; progress on debt reduction and interest rate trends will be key to achieving guidance.
Profitability divergence across segments is pronounced. Diabetes Management (margin 19.8%, profit +44.6%) is driving the group, while Healthcare Solutions (margin 4.9%, -32.8%) and Diagnostics & Life Sciences (margin 3.0%, -46.3%) continue low-margin operations that dilute group margins. Price revisions, cost reduction, or portfolio restructuring in the two low-margin segments are essential for medium-term profitability improvement; progress in structural transformation will be watched closely.
High dependency on goodwill ¥2,215B (138% of equity) and intangibles, abnormal effective tax rate of 96.6%, and weakened working capital efficiency (DIO 97 days, DSO 70 days) remain latent risks. Comprehensive income ¥241.4B was lifted by non-cash FX effects and does not reflect recurring profit; sustainability is limited. Investment decisions should await confirmation of improving trends on three structural issues: reduction in interest burden, normalization of tax rate, and profitability improvement in low-margin segments.
This report was auto-generated by AI analyzing XBRL financial statement data. It does not constitute a recommendation to invest in any specific securities. Industry benchmarks are reference information compiled by the firm based on public financial statements. Investment decisions are your responsibility; consult a professional advisor as needed.